nuedexta
jenson pharmaceutical services limited - dekstrometorfan, kinidin - neurobehavioral manifestations - andre nervesystemet narkotika - nuedexta er indisert for symptomatisk behandling av pseudobulbarpåvirkning (pba) hos voksne. effekt har kun blitt studert hos pasienter med underliggende amyotrofisk lateralsklerose eller multippel sklerose.
primovist 0.25 mmol/ ml
bayer ab - solna - dinatriumgadoksetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 0.25 mmol/ ml
escitalopram bluefish 10 mg
bluefish pharmaceuticals ab - escitalopramoksalat - tablett, filmdrasjert - 10 mg
escitalopram bluefish 5 mg
bluefish pharmaceuticals ab - escitalopramoksalat - tablett, filmdrasjert - 5 mg
escitalopram bluefish 20 mg
bluefish pharmaceuticals ab - escitalopramoksalat - tablett, filmdrasjert - 20 mg
naproxen evolan 250 mg
evolan pharma ab - naproksen - tablett - 250 mg
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
escitalopram mylan 10 mg
mylan ab - escitalopramoksalat - tablett, filmdrasjert - 10 mg
escitalopram mylan 5 mg
mylan ab - escitalopramoksalat - tablett, filmdrasjert - 5 mg
escitalopram mylan 20 mg
mylan ab - escitalopramoksalat - tablett, filmdrasjert - 20 mg